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The G-protein regulatory (GPR) motif, a conserved
25–30 amino acid domain found in multiple mammalian
proteins, stabilizes the GDP-bound conformation of Gi,
inhibits guanosine 5-O-(3-thiotriphosphate) (GTPS)
binding to Gi and competes for G binding to G. To
define the core GPR motif and key amino acid residues
within a GPR peptide (TMGEEDFFDLLAKSQSKRMD-
DQRVDLAG), we determined the effect of truncation,
insertion, and alanine substitutions on peptide-medi-
ated inhibition of GTPS binding to purified Gi1. The
bioactive core GPR peptide consists of 17 amino acids
(7F–R23). Within this core motif, two hydrophobic sec-
tors (7FF8 and 10LL11) and Q22 are required for bioactiv-
ity, whereas M19A and R23A increased IC50 values by
70-fold. Disruption of spatial relationships between the
required sectors in the amino and carboxyl regions of
the peptide also resulted in a loss of biological activity.
Mutation of three charged sectors (4EED6, R18, 20DD21)
within the 28-amino acid GPR decreased peptide affin-
ity by 10-fold. Alanine substitutions of selected resi-
dues within the core GPR peptide differently influenced
peptide inhibition of GTPS binding to Gi versus Go.
These data provide a platform for the development of
novel, G-protein-selective therapeutics that inhibit Gi-
mediated signaling, selectively activate G-sensitive
effectors, and/or disrupt specific regulatory input to G-
proteins mediated by GPR-containing proteins.
The activation/deactivation cycle of heterotrimeric G-pro-
teins, key players in cell signaling events, involves guanine
nucleotide exchange, GTP hydrolysis, and a number of dy-
namic, conformationally sensitive protein interactions. In ad-
dition to the extensively studied activation of G-proteins by the
superfamily of G-protein-coupled receptors, the G-protein acti-
vation/deactivation cycle is regulated by nonreceptor proteins
that influence subunit interactions, GTPase activity, and gua-
nine nucleotide binding properties of G. One signature motif
for such regulatory proteins is the regulator of G-protein sig-
naling (RGS)1 domain, a 120-amino acid motif found in all
members of the RGS family (1). Another signature motif
(25–30 amino acids) is defined by the G-protein regulatory
(GPR) domain in activator of G-protein signaling (AGS) 3 (2–6),
which was discovered in a functional screen for receptor-inde-
pendent activators of G-protein signaling. The GPR motif was
also recognized in RGS12 and RGS14 by general sequence
analysis/alignment and termed the GoLOCO motif (7, 8).
Surprisingly, interaction of the GPR motif with Gi stabi-
lizes the GDP bound conformation of Gi, competes with G
for G binding, and inhibits guanine nucleotide exchange (3–6,
9–12). Thus, the GPR motif acts as a guanine nucleotide dis-
sociation inhibitor of Gi. The GPR motif is evolutionarily
conserved within individual orthologs and among proteins with
apparently diverse functions (see S.M.A.R.T. data base at
dylan.embl-heidelberg.de/). Four spatially conserved GPR mo-
tifs are found in AGS3 (3) and LGN (13), which were isolated
as Gi-regulatory/binding proteins. Recombinant AGS3 con-
structs with more than one GPR motif actually bind more than
one Gi at the same time (5), suggesting a scaffolding role for
such proteins. The AGS3/LGN-related protein PINS, which
plays key roles in cell polarity (14–17), possesses a similar
domain structure. The interaction of the PINS protein GPR
domains with G is involved in the function of PINS in cell
polarity and asymmetric cell division (17). AGS3 is also in-
volved in synaptic adaptation in rat models of addiction (22).
Single GPR motifs are found in Rap1GAP, Pcp2, RGS12, and
RGS14, which are all implicated as G-protein regulators. Pro-
tein interaction studies and/or functional screens in yeast in-
dicate that the AGS3 GPR motif interacts with Gi1–3, but not
Gs, Gq, Gz, G12, or G16 (3, 5, 11). Specific GPR motifs are
capable of interacting with Go, albeit with apparently lower
affinity than observed for Gi (10). Rap1GAP was actually
isolated in yeast two-hybrid screens using Go (18) and Gz
(19), whereas Pcp2 was isolated in similar screens using Go
(20). Thus the GPR motif appears to serve as a discrete motif to
anchor a variety of proteins that influence the guanine nucle-
otide binding/hydrolysis properties of G-proteins.
The existence of such a fairly discrete and highly conserved
binding motif that inhibits GDP dissociation is of particular
interest. As a first step toward developing a small organic
molecule that would mimic the action of a GPR peptide, we
defined the key structural features of the GPR motif required
for biological activity. These data provide a platform for the
development of novel, G-protein-selective therapeutics that
target this critically important signaling protein within the
cell. Such agents might inhibit G-mediated signaling by G-
protein-coupled receptors, selectively activate G-sensitive ef-
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fectors, and/or disrupt specific regulatory input to G-proteins
mediated by GPR-containing proteins.
EXPERIMENTAL PROCEDURES
Materials—Peptides were synthesized and purified by Bio-Synthesis,
Inc. (Lewisville, TX) and peptide identity verified by matrix-assisted
laser desorption ionization mass spectrometry. Peptides were synthe-
sized with an acetylated amino terminus and an amidated carboxyl
terminus. All other materials were obtained as described elsewhere
(3–5).
GTPS Binding and Protein Interaction Assays—GTPS binding
assays and protein interaction assays were conducted as described
previously (4, 5). The GPR domain of AGS3 (463P–S650) was generated
as a gutathione S-transferase fusion protein in pGEX4T1. GST-AGS3
was expressed in and purified from BL21 bacteria using glutathione-
Sepharose 4B. Gi1 and Go were purified in the GDP bound state from
Sf9 insect cells infected with recombinant virus as described previously
(21). Concentration response curves with GPR peptides were analyzed
by PRISM (Graphpad Software, Inc, San Diego, CA) to calculate IC50
values.
RESULTS AND DISCUSSION
Stabilization of the GDP-bound conformation of Gi by a
28-amino acid peptide encompassing the GPR motif presents
an unexpected aspect of regulation within the G-protein acti-
vation/deactivation cycle. This activity of the peptide essen-
tially prevents nucleotide exchange on G and binding of GTP
to G-protein. The GPR-GiGDP complex is quite stable and is
observed in the absence and presence of added magnesium,
which is generally required for high affinity binding of GTPS
(Fig. 1). As part of a broad approach to define the structural
properties of this regulation and develop a small molecule
ligand that would target this novel regulatory site on G sub-
units, we defined the core GPR motif and the key amino acid
residues within this core motif. A panel of peptides derived
from the GPR motif were characterized in GTPS binding
assays and protein interaction assays using purified mamma-
lian G-protein  subunits.
Several conserved features constitute the GPR motif. The
invariant Q15 essentially divides the peptide into two general
regions of conserved residues (Fig. 2A). Both helical wheel and
hydrophobic moment analysis indicate that the area upstream
of Q15 likely exists as an alpha helix. We first asked if either of
the two general regions of conserved residues (i.e. upstream
and downstream of Q15) were active by themselves. Neither
GPR1–15 nor GPR15–28 inhibited GTPS binding to Gi. The
region upstream of Q15 is distinguished by the negatively
charged 4EED6 followed by two hydrophobic sectors (7FF8,
10LL11) (Fig. 2). The region downstream of the Q15 peptide is
characterized by the conserved sequence 18RMDDQR23. Dele-
tion of the first eight residues at the amino terminus, which
removed 7FF8 or mutation of R23 to phenylalanine (3–5), re-
sulted in an inactive peptide indicating that the minimal se-
quence for bioactivity is 7F–R23 (Fig. 2A). The 20DDQR23 se-
quence is one of the most highly conserved regions of the
peptide among different species and proteins. To test the
importance of the spatial relationship between this region and
the remainder of the conserved residues found elsewhere in the
peptide, we inserted two and four alanines just upstream of the
20DDQR23 region. Insertion of the alanines completely abol-
ished bioactivity in GTPS binding assays (Fig. 2A). Thus,
these data indicated that there is a core GPR motif (residues
7–23) in which a defined spatial relationship among the con-
served residues is required for bioactivity.
We then addressed the relative importance of conserved
amino acids within the core GPR motif by alanine substitutions
and subsequent peptide evaluation in GTPS binding assays
(Fig. 2B). Peptides with alanine substitutions at 7FF8, 10LL11,
and Q22 were inactive and thus identify the key residues of the
peptide. Both 7FF8 and 10LL11 likely constitute the core of the
predicted alpha helix in this region, indicating the importance
of this structural feature for bioactivity (Fig. 1). The impor-
tance of this region is further emphasized by loss of biological
activity observed with an F8R mutation in the context of a
GST-AGS3 fusion protein (3, 5, 17). The IC50 values for D9A,
K13A, Q15A, and S16A peptides were similar to the consensus
GPR peptide (Fig. 2B). Alanine substitutions at the other key
residues within the GPR motif indicated that the residues
could be grouped as those causing 7–10-fold (4EED6, R18, and
20DD21) or 50–70-fold (M19 and R23) shifts in IC50 values (Fig.
FIG. 1. Effect of magnesium on inhibition of GTPS binding to
Gi. GTP
35S (500 nM) binding (using 0 and 25 mM MgCl2) to Gi (100
nM) was measured in absence and presence of increasing amounts of
GPR peptide as described under “Experimental Procedures.” Data are
expressed as the percent of specific binding (2 pmol) observed in the
absence of added peptide and are expressed as the mean  S.E. of two
experiments with duplicate determinations.
FIG. 2. Identification of the core GPR motif. A: left panel, amino
acid sequence of GPR peptide and truncated GPR peptides. Consensus
amino acids are depicted in red. The right panel portrays GTPS bind-
ing (500 nM with 2 mM MgCl2) to Gi (100 nM) measured in the absence
and presence of GPR peptides (100 M) as described under “Experimen-
tal Procedures.” Data are expressed as the percent of specific binding
(1 pmol) observed in the absence of added peptide and are expressed
as the mean  S.E. of two experiments with duplicate determinations.
Similar results were obtained in two to five separate experiments. B:
left panel, sequence alignment and IC50 values of mutated GPR pep-
tides. Conserved amino acids are depicted in red, and mutated amino
acids are colored green. Right panel, effect of increasing concentrations
of competing peptides on GTPS (500 nM with 2 mM MgCl2) binding to
Gi (100 nM). Data are expressed as the percent of specific binding (1
pmol) observed in the absence of added peptide and are expressed as the
mean  S.E. of two experiments with duplicate determinations. Similar
results were obtained in two to five separate experiments. Inactive,
inhibition of GTPS binding was less than 30% at peptide concentra-
tions of 100 M.
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2B). The loss of affinity observed with the alanine substitutions
at 4EED6 are consistent with the retention of bioactivity by the
truncation mutant GPR3–24, whereas the loss of activity with
the 7FF8 alanine substitutions was also observed by elimina-
tion of these residues in the GPR10–24 truncated peptide. The
larger reduction in affinity observed with the M19 and R23
alanine substitutions indicate the importance of these residues
within the core GPR peptide. Indeed, reversal of charge or
hydrophobicity at these residues (M19D and R23F) essentially
rendered these peptides inactive (3–5).2
The inhibition of GTPS binding and apparent stabilization
of the GDP-bound conformation of Gi by the GPR peptide
likely involves two events, the initial binding of the peptide to
G-protein, followed by a conformational change in Gi itself. To
determine whether the two events can be functionally dissoci-
ated, we performed two series of experiments. We first asked if
mutant peptides that exhibited lower affinity in GTPS bind-
ing assays were also deficient in inhibiting binding of a GPR-
containing GST-AGS3 fusion protein to Gi. In the second
series of experiments, we determined whether truncated GPR
peptides could act in a complementary fashion and whether
they could antagonize the action of the GPR consensus peptide.
Data generated from this series of experiments indicated that
the loss of function in binding studies was also reflected in the
protein interaction assays (Fig. 3, A and B). The partial inhi-
bition of GST-AGS3 binding to G-protein in the presence of
GPR6–24 indicates that this peptide is not as potent as
GPR3–24 or wild type peptide, likely due to the loss of the
4EED6 acidic cluster (Fig. 2, A and B, and Fig. 3B). These data
indicated that G-protein interaction and inhibition of GTPS
binding could not be dissociated from each other. This point is
further emphasized by data generated in another series of
experiments (Fig. 3C). A combination of the inactive GPR trun-
cation peptides (GPR 1–15 and GPR 15–28) did not inhibit
binding of GST-AGS3 to Gi. Neither of the peptides antago-
nized the action of the consensus GPR peptide nor were they
able to rescue the activity of nonfunctional, alanine-substituted
GPR peptides (Fig. 3). These data confirm the importance of
the spatial relationship within the core GPR motif. These data
also indicate that the GPR domain must function as an intact
unit and that there are multiple points of contact between the
GPR domain and G.
Although the GPR peptide clearly prefers Gi over Go,
subtle mutations within the core motif differentially effect pep-
tide interaction with the two G-proteins (Fig. 4A). A screen of
the mutant GPR peptides for selectivity indicated that inhibi-
tion of GTPS binding to Go is completely eliminated by
alanine substitutions within the core GPR motif that only
minimally altered GTPS binding to Gi (Fig. 4A). The differ-
ence in the interaction of the GPR peptide with Gi versus Go
is also observed by comparing the relative inhibition of GTPS
binding in the presence and absence of magnesium. The inhi-
bition of GTPS binding to Go is much more sensitive to
magnesium as compared with the effects of the peptide on Gi
(Fig. 4B). These data indicate that the GPR peptides can dif-
ferentially target G-protein  subunits. Amino acids outside
the GPR motif may also influence G-protein selectivity or bio-
activity (see Discussion in Ref. 4).3
The core GPR motif identified in the present study is indi-
cated in Sequence 1.
FF-LL-------M--QR
SEQUENCE 1
Within this core, 7FF8, 10LL11, and Q22 are absolutely required
for bioactivity. The carboxyl terminus R23 and the M19 residue
also play key roles in bioactivity as their mutation results in




4EE5, 20DD21, and the internal R18 all exert effects on affinity
(7–10-fold). Minimizing the core GPR motif to its essential
pharmacophores identified the chemical moieties within the
GPR motif that regulate Gi/Go nucleotide exchange. By virtue
2 Y. K. Peterson and S. M. Lanier, unpublished observations.
3 R. Kimple, J. Sondek, and D. P. Siderovski, personal
communication.
FIG. 3. Effect of GPR peptides on binding of Gi to AGS3. Protein
interaction assays were performed as described under “Experimental
Procedures” using 75 nM Gi1 and 300 nM GST-AGS3 in the presence of 10
M GDP. Peptide concentration is 100 M in A and B. The peptide
concentration was 10 M in C except for the four lanes at the right of the
panel where the truncated GPR peptides were present at 100 M. Similar
results were obtained in two to three separate experiments.
FIG. 4. Effect of GPR peptides on GTPS binding to Gi versus
Go. A, GTP
35S binding (500 nM) to purified G-protein (100 nM) was
determined as described under “Experimental Procedures” as detailed
in the legend to Fig. 1 in the absence and presence of 10 M peptide.
Assays were conducted in parallel using the same stocks of GTPS and
peptides. Data are expressed as the percent of specific binding (Gi  2
pmol, Go  1 pmol). B, GTP
35S (500 nM) binding (using 0 and 25 mM
MgCl2) to Gi or Go (100 nM) was measured in absence and presence of
100 M GPR peptide as described under “Experimental Procedures.”
The increased GTPS binding to Go in the presence of selected pep-
tides was also observed with similar amounts of bovine serum albumin,
suggesting that it does not likely represent an actual increase in nucle-
otide exchange, per se, but rather enhanced protein recovery. Data are
expressed as the percent of specific binding (1 pmol for Gi and Go)
observed in the absence of added peptide and are expressed as the
mean  S.E. of two experiments with duplicate determinations.
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of its novel mode of regulation of G-proteins, the core GPR
motif provides an unexpected platform for the development of
G-protein selective therapeutics.
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